Summary

This report is an essential source for in-depth information and data relating to Germany In vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and the latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in Germany

Scope

-The report provides information on the German in vitro diagnostics market, broken down into detailed categories and segments such as In Vitro Diagnostics, Clinical Chemistry Test Reagents, Immunochemistry Test Reagents, Blood Test Reagents, Microbiology Test Reagents, Infectious Immunology, Test Reagents, Genetic Test Reagents, Self Testing, and Instruments.
-Total revenues, end users
-Market shares of all the key competitors.
-Key pipeline products that are set to shape the market, broken down by sector.
-Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
-Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
-Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
-Key mergers and acquisitions, partnerships, private equity investments and IPOs.
-Customer, hospitals and physicians data.

Reasons to buy

-Gain a strong understanding of the in vitro diagnostics devices market in Germany.
-Evaluate and compare the attractiveness of the market in the country.
-Identify growth segments and opportunities in each industry sector within the country.
-Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
-Analyze the competitiveness of the market in the country and identify hotspots.
-Develop strategies based on the latest product, brand, expansion and research and development news in the country.
-Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
-Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Table of Contents

1.1 List of Tables 13
1.2 List of Figures 17
2 Introduction 19
2.1 What Is This Report About? 19
3 Definitions of Markets Covered in This Report 20
3.1 In Vitro Diagnostics 20
3.2 Clinical Chemistry 20
3.2.1 Clinical Chemistry Rapid Tests & POC 20
3.2.2 Clinical Chemisty Analyzers 20
3.2.2.1 Automated Clinical Chemistry Analyzers 20
3.2.2.2 Semi-Automated Clinical Chemistry Analyzers 20
3.2.3 Electrolyte Chemistry Reagents 20
3.2.4 Enzyme Chemistry Reagents 21
3.2.5 Metabolite Chemistry Reagents 21
3.2.6 Urine Analysis 21
3.2.6.1 Urine Analyzer Reagents 21
3.2.6.2 Urine Analyzers 21
3.3 Genetic Testing 21
3.3.1 Acquired Gene or Chromosome Alterations 21
3.3.2 Inborn Gene or Chromosome Alterations 21
3.3.3 Other Genetic Tests 21
3.4 Haematology 21
3.4.1 Haematology Analyzers 21
3.4.2 Haematology Cell Counters 22
3.4.2.1 Differential Counters 22
3.4.2.2 Hemoglobinometers 22
3.4.3 Haematology Rapid Tests 22
3.4.3.1 Haemostasis Rapid Tests (Home Monitoring) 22
3.4.3.2 Rapid Haematology Tests (Point-Of-Care/Near Patient) 22
3.4.4 Haematology Reagents 22
3.4.4.1 Haematology Analyzer Reagents 22
3.4.4.2 Slide Stainers 22
3.4.5 Haemostasis 22
3.4.5.1 Coagulation Analyzers 22
3.4.5.2 Coagulation Factors 22
3.4.5.3 General Coagulation Tests 22
3.4.5.4 Platelet Factors 23
3.4.5.5 Special Coagulation Tests 23
3.4.6 Immunohaematology 23
3.4.6.1 ABO Typing 23
3.4.6.2 Antibody Detection 23
3.4.6.3 Rhesus Typing 23
3.5 Histology And Cytology 23
3.5.1 Cytology 23
3.5.1.1 Flow Cytometers 23
3.5.2 Histology 23
3.5.2.1 Monoclonal Antibodies 23
3.5.2.2 Tissue Typing Reagents 23
3.6 Immuno Chemistry 24
3.6.1 Disease Specific Immunochemistry 24
3.6.1.1 Auto-Immune Diseases 24
3.6.1.2 Cardiac Markers 24
3.6.1.3 Rheumatoid -Inflammatory Diseases Markers 24
3.6.1.4 Tumor markers 24
3.6.2 Drug Related Testing 24
3.6.2.1 Drugs of Abuse / Toxicology 24
3.6.2.2 Therapeutic Drug Monitoring 24
3.6.3 Endocrinology Tests 25
3.6.3.1 Fertility or Pregnancy Hormones 25
3.6.3.2 Individual and Specified Hormones 25
3.6.3.3 Thyroid Function Hormones 25
3.6.4 Immunochemistry Analyzers 25
3.6.4.1 Chemiluminescence Analyzers 25
3.6.4.2 ELISA Instruments 25
3.6.4.3 Immunofluorescence Analyzers 25
3.6.4.4 Radioimmunoassay Analyzers 25
3.6.5 Immunochemistry Rapid Tests 25
3.6.6 Organ Function Assays 25
3.6.7 Specific Proteins 26
3.7 Infectious Immunology 26
3.7.1 Bacteriology 26
3.7.2 Hepatitis Viruses 26
3.7.3 Other Virology 26
3.7.4 Retroviruses 26
3.8 Microbiology Culture 26
3.8.1 Bacterial Identification & Susceptibility Testing 26
3.8.2 Blood Culture 26
3.8.3 Immunological Culture Identification 26
3.8.4 Microbiology Analyzers 26
3.8.4.1 Automated Microbiology Analyzers 26
3.8.4.2 Semi-Automated Microbiology Analyzers 27
3.8.5 Mycobacteria Culture 27
3.8.6 Mycology Culture 27
3.8.7 Parasitology Culture 27
4 Healthcare Sector Review 28
4.1 Healthcare Sector 28
4.2 Healthcare Expenditure 28
4.3 Healthcare Infrastructure 31
4.3.1 Healthcare Personnel Data 31
4.3.2 Healthcare Facilities Data 33
4.4 Healthcare Policy 38
5 Regulation System 39
5.1 Regulation System 39
5.2 Medical Equipment Approval Process 39
5.2.1 Classification of Medical Devices 39
5.3 Conformity Assessment Process 48
5.3.1 Class I devices 48
5.3.2 Class IIa devices 49
5.3.3 Class IIb devices 50
5.3.4 Class III devices 51
5.4 Post Market Surveillance 52
6 Pricing and Reimbursement 53
6.1 SHI 53
6.1.1 Private Health Insurance 53
6.1.2 Diagnosis Related Groups (DRG) 53
7 Distribution Structure 54
8 In Vitro Diagnostics In Germany 55
8.1 In Vitro Diagnostics, Germany, Overall Revenue ($ mn), 2000-2015 55
8.2 In Vitro Diagnostics, Germany, Company Share (2007-2008) 61
9 Clinical Chemistry In Germany 62
9.1 Clinical Chemistry Overall Revenue (2000-2015) 62
9.1.1 Clinical Chemistry Analyzers Revenue (2000-2015) 66
9.1.2 Urine Analysis Revenue (2000-2015) 68
9.2 Clinical Chemistry Distribution Share (2007-2008) 70
9.3 Clinical Chemistry, Germany, Company Share (2007-2008) 71
10 Genetic Testing In Germany 72
10.1 Genetic Testing Overall Revenue (2000-2015) 72
10.2 Genetic Testing Distribution Share (2007-2008) 74
10.3 Genetic Testing, Germany, Company Share (2007-2008) 75
11 Haematology In Germany 76
11.1 Haematology Overall Revenue (2000-2015) 76
11.1.1 Haematology Reagents Revenue (2000-2015) 80
11.1.2 Immunohaematology Revenue (2000-2015) 82
11.1.3 Haemostasis Revenue (2000-2015) 84
11.1.4 Haematology Rapid Tests Revenue (2000-2015) 88
11.1.5 Haematology Cell Counters Revenue (2000-2015) 90
11.2 Haematology Distribution Share (2007-2008) 92
11.3 Haematology, Germany, Company Share (2007-2008) 93
12 Histology and Cytology In Germany 95
12.1 Histology and Cytology Overall Revenue (2000-2015) 95
12.1.1 Histology Revenue (2000-2015) 97
12.2 Histology and Cytology Distribution Share (2007-2008) 99
12.3 Histology and Cytology, Germany, Company Share (2007-2008) 100
13 Immuno Chemistry In Germany 101
13.1 Immuno Chemistry Overall Revenue (2000-2015) 101
13.1.1 Disease Specific Immunochemistry Revenue (2000-2015) 105
13.1.2 Drug Related Testing Revenue (2000-2015) 109
13.1.3 Endocrinology Tests Revenue (2000-2015) 111
13.1.4 Immunochemistry Analyzers Revenue (2000-2015) 113
13.2 Immuno Chemistry Distribution Share (2007-2008) 117
13.3 Immuno Chemistry, Germany, Company Share (2007-2008) 118
14 Infectious Immunology In Germany 120
14.1 Infectious Immunology Overall Revenue (2000-2015) 120
14.2 Infectious Immunology Distribution Share (2007-2008) 124
14.3 Infectious Immunology, Germany, Company Share (2007-2008) 125
15 Microbiology Culture In Germany 127
15.1 Microbiology Culture Overall Revenue (2000-2015) 127
15.1.1 Microbiology Analyzers Revenue (2000-2015) 131
15.2 Microbiology Culture Distribution Share (2007-2008) 133
15.3 Microbiology Culture, Germany, Company Share (2007-2008) 134
16 Overview of Key Companies in Germany In Vitro Diagnostics Market 135
16.1 Ventana Medical Systems, Inc. 135
16.1.1 Company Overview 135
16.2 Sysmex Corporation 135
16.2.1 Company Overview 135
16.2.2 Sysmex Corporation Pipeline Products 135
16.2.2.1 Sysmex Corporation Pipeline Products By Equipment Type 135
16.2.2.2 Sysmex Corporation Pipeline Products By Development Stage 135
16.2.2.3 Sysmex Corporation Pipeline Products By Therapy Area 136
16.2.2.4 Sysmex Corporation Pipeline Products By News Summary 136
16.3 Siemens Healthcare 137
16.3.1 Company Overview 137
16.4 Qiagen N.V. 137
16.4.1 Company Overview 137
16.4.2 Qiagen N.V. Pipeline Products 138
16.4.2.1 Qiagen N.V. Pipeline Products By Equipment Type 138
16.4.2.2 Qiagen N.V. Pipeline Products By Development Stage 138
16.4.2.3 Qiagen N.V. Pipeline Products By Therapy Area 139
16.4.2.4 Qiagen N.V. Pipeline Products By News Summary 139
16.5 Phadia AB 140
16.5.1 Company Overview 140
16.5.2 Phadia AB Pipeline Products 140
16.5.2.1 Phadia AB Pipeline Products By Equipment Type 140
16.5.2.2 Phadia AB Pipeline Products By Development Stage 140
16.5.2.3 Phadia AB Pipeline Products By Therapy Area 141
16.5.2.4 Phadia AB Pipeline Products By News Summary 141
16.6 Ortho-Clinical Diagnostics Inc. 142
16.6.1 Company Overview 142
16.6.2 Ortho-Clinical Diagnostics Inc. Pipeline Products 142
16.6.2.1 Ortho-Clinical Diagnostics Inc. Pipeline Products By Equipment Type 142
16.6.2.2 Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage 143
16.6.2.3 Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area 143
16.7 OLYMPUS CORPORATION 144
16.7.1 Company Overview 144
16.8 Inverness Medical Innovations, Inc. 144
16.8.1 Company Overview 144
16.8.2 Inverness Medical Innovations, Inc. Pipeline Products 145
16.8.2.1 Inverness Medical Innovations, Inc. Pipeline Products By Equipment Type 145
16.8.2.2 Inverness Medical Innovations, Inc. Pipeline Products By Development Stage 145
16.8.2.3 Inverness Medical Innovations, Inc. Pipeline Products By Therapy Area 146
16.8.2.4 Inverness Medical Innovations, Inc. Pipeline Products By Clinical Trials 146
16.8.2.5 Inverness Medical Innovations, Inc. Pipeline Products By News Summary 146
16.9 Hologic, Inc. 147
16.9.1 Company Overview 147
16.9.2 Hologic, Inc. Pipeline Products 147
16.9.2.1 Hologic, Inc. Pipeline Products By Equipment Type 147
16.9.2.2 Hologic, Inc. Pipeline Products By Development Stage 148
16.9.2.3 Hologic, Inc. Pipeline Products By Therapy Area 148
16.9.2.4 Hologic, Inc. Pipeline Products By Clinical Trials 148
16.9.2.5 Hologic, Inc. Pipeline Products By News Summary 149
16.10 Gen-Probe Incorporated 150
16.10.1 Company Overview 150
16.10.2 Gen-Probe Incorporated Pipeline Products 150
16.10.2.1 Gen-Probe Incorporated Pipeline Products By Equipment Type 150
16.10.2.2 Gen-Probe Incorporated Pipeline Products By Development Stage 151
16.10.2.3 Gen-Probe Incorporated Pipeline Products By Therapy Area 151
16.10.2.4 Gen-Probe Incorporated Pipeline Products By Clinical Trials 151
16.10.2.5 Gen-Probe Incorporated Pipeline Products By News Summary 152
16.11 F. Hoffmann-La Roche Ltd. 153
16.11.1 Company Overview 153
16.12 DiaSorin S.p.A 153
16.12.1 Company Overview 153
16.12.2 DiaSorin S.p.A Pipeline Products 154
16.12.2.1 DiaSorin S.p.A Pipeline Products By Equipment Type 154
16.12.2.2 DiaSorin S.p.A Pipeline Products By Development Stage 154
16.12.2.3 DiaSorin S.p.A Pipeline Products By Therapy Area 154
16.13 Dade Behring Holdings, Inc. 155
16.13.1 Company Overview 155
16.14 Bio-Rad Laboratories, Inc. 155
16.14.1 Company Overview 155
16.15 bioMerieux S.A. 156
16.15.1 Company Overview 156
16.16 Becton, Dickinson and Company 156
16.16.1 Company Overview 156
16.16.2 Becton, Dickinson and Company Pipeline Products 157
16.16.2.1 Becton, Dickinson and Company Pipeline Products By Equipment Type 157
16.16.2.2 Becton, Dickinson and Company Pipeline Products By Development Stage 158
16.16.2.3 Becton, Dickinson and Company Pipeline Products By Therapy Area 158
16.16.2.4 Becton, Dickinson and Company Pipeline Products By Clinical Trials 159
16.16.2.5 Becton, Dickinson and Company Pipeline Products By News Summary 159
16.17 Beckman Coulter, Inc. 160
16.17.1 Company Overview 160
16.17.2 Beckman Coulter, Inc. Pipeline Products 160
16.17.2.1 Beckman Coulter, Inc. Pipeline Products By Equipment Type 160
16.17.2.2 Beckman Coulter, Inc. Pipeline Products By Development Stage 161
16.17.2.3 Beckman Coulter, Inc. Pipeline Products By Therapy Area 162
16.17.2.4 Beckman Coulter, Inc. Pipeline Products By News Summary 162
16.18 Abbott Laboratories 163
16.18.1 Company Overview 163
16.18.2 Abbott Laboratories Pipeline Products 163
16.18.2.1 Abbott Laboratories Pipeline Products By Equipment Type 163
16.18.2.2 Abbott Laboratories Pipeline Products By Development Stage 163
16.18.2.3 Abbott Laboratories Pipeline Products By Therapy Area 163
16.19 AdnaGen AG 164
16.19.1 Company Overview 164
16.19.2 AdnaGen AG Pipeline Products 164
16.19.2.1 AdnaGen AG Pipeline Products By Equipment Type 164
16.19.2.2 AdnaGen AG Pipeline Products By Development Stage 164
16.19.2.3 AdnaGen AG Pipeline Products By Therapy Area 165
16.19.2.4 AdnaGen AG Pipeline Products By Clinical Trials 165
16.19.2.5 AdnaGen AG Pipeline Products By News Summary 165
16.20 AMODIA Bioservice GmbH 166
16.20.1 Company Overview 166

1.1 List of Tables
Table 1: Healthcare Expenditure in Germany, (€m), 2000 ¨C 2006 28
Table 2: Healthcare Personnel by Region in Germany, 2007 31
Table 3: Doctors by Specialty in Germany, 2000-2004 32
Table 4: Hospitals by Region in Germany, 2004 33
Table 5: Hospitals and Beds by Region in Germany, 2007 34
Table 6: Rehabilitation Centers by Region in Germany, 2004 35
Table 7: Rehabilitation Center Beds by Region in Germany, 2004 36
Table 8: Discharges by Diagnosis in Germany, 2004 37
Table 9:In Vitro Diagnostics, Germany, Overall Revenue ($ mn), 2000-2015 55
Table 10: In Vitro Diagnostics, Germany, Cross-Category Analysis, 2000-2015 56
Table 11:In Vitro Diagnostics, Germany, Overall Revenue ($ mn), Historic, 2000-2008 58
Table 12:In Vitro Diagnostics, Germany, Overall Revenue ($ mn), Forecast, 2008-2015 60
Table 13:In Vitro Diagnostics, Germany, Company Share by Revenue ($ mn), 2007-2008 61
Table 14:Clinical Chemistry, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 63
Table 15:Clinical Chemistry, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 65
Table 16:Clinical Chemistry Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 66
Table 17:Clinical Chemistry Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 67
Table 18:Urine Analysis, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 68
Table 19:Urine Analysis, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 69
Table 20:Clinical Chemistry, Germany, Distribution Share by Revenue ($mn), 2007-2008 70
Table 21:Clinical Chemistry, Germany, Company Share by Revenue ($ mn), 2007-2008 71
Table 22:Genetic Testing, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 72
Table 23:Genetic Testing, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 73
Table 24:Genetic Testing, Germany, Distribution Share by Revenue ($mn), 2007-2008 74
Table 25:Genetic Testing, Germany, Company Share by Revenue ($ mn), 2007-2008 75
Table 26:Haematology, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 77
Table 27:Haematology, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 79
Table 28:Haematology Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 80
Table 29:Haematology Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 81
Table 30:Immunohaematology, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 82
Table 31:Immunohaematology, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 83
Table 32:Haemostasis, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 85
Table 33:Haemostasis, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 87
Table 34:Haematology Rapid Tests, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 88
Table 35:Haematology Rapid Tests, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 89
Table 36:Haematology Cell Counters, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 90
Table 37:Haematology Cell Counters, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 91
Table 38:Haematology, Germany, Distribution Share by Revenue ($mn), 2007-2008 92
Table 39:Haematology, Germany, Company Share by Revenue ($ mn), 2007-2008 94
Table 40:Histology And Cytology, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 95
Table 41:Histology And Cytology, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 96
Table 42:Histology, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 97
Table 43:Histology, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 98
Table 44:Histology and Cytology, Germany, Distribution Share by Revenue ($mn), 2007-2008 99
Table 45:Histology And Cytology, Germany, Company Share by Revenue ($ mn), 2007-2008 100
Table 46:Immuno Chemistry, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 102
Table 47:Immuno Chemistry, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 104
Table 48:Disease Specific Immunochemistry, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 106
Table 49:Disease Specific Immunochemistry, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 108
Table 50:Drug Related Testing, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 109
Table 51:Drug Related Testing, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 110
Table 52:Endocrinology Tests, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 111
Table 53:Endocrinology Tests, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 112
Table 54:Immunochemistry Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 114
Table 55:Immunochemistry Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 116
Table 56:Immuno Chemistry, Germany, Distribution Share by Revenue ($mn), 2007-2008 117
Table 57:Immuno Chemistry, Germany, Company Share by Revenue ($ mn), 2007-2008 119
Table 58:Infectious Immunology, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 121
Table 59:Infectious Immunology, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 123
Table 60:Infectious Immunology, Germany, Distribution Share by Revenue ($mn), 2007-2008 124
Table 61:Infectious Immunology, Germany, Company Share by Revenue ($ mn), 2007-2008 126
Table 62:Microbiology Culture, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 128
Table 63:Microbiology Culture, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 130
Table 64:Microbiology Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 131
Table 65:Microbiology Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 132
Table 66:Microbiology Culture, Germany, Distribution Share by Revenue ($mn), 2007-2008 133
Table 67:Microbiology Culture, Germany, Company Share by Revenue ($ mn), 2007-2008 134
Table 68:Sysmex Corporation Pipeline Products by Equipment Type 135
Table 69:Sysmex Corporation Pipeline Products By Development Stage 135
Table 70:Sysmex Corporation Pipeline Products By Therapy Area 136
Table 71:Sysmex Corporation Pipeline Products By News Summary 136
Table 72:Qiagen N.V. Pipeline Products by Equipment Type 138
Table 73:Qiagen N.V. Pipeline Products By Development Stage 138
Table 74:Qiagen N.V. Pipeline Products By Therapy Area 139
Table 75:Qiagen N.V. Pipeline Products By News Summary 139
Table 76:Phadia AB Pipeline Products by Equipment Type 140
Table 77:Phadia AB Pipeline Products By Development Stage 140
Table 78:Phadia AB Pipeline Products By Therapy Area 141
Table 79:Phadia AB Pipeline Products By News Summary 141
Table 80:Ortho-Clinical Diagnostics Inc. Pipeline Products by Equipment Type 142
Table 81:Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage 143
Table 82:Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area 143
Table 83:Inverness Medical Innovations, Inc. Pipeline Products by Equipment Type 145
Table 84:Inverness Medical Innovations, Inc. Pipeline Products By Development Stage 145
Table 85:Inverness Medical Innovations, Inc. Pipeline Products By Therapy Area 146
Table 86:Inverness Medical Innovations, Inc. Pipeline Products By Clinical Trials 146
Table 87:Inverness Medical Innovations, Inc. Pipeline Products By News Summary 146
Table 88:Hologic, Inc. Pipeline Products by Equipment Type 147
Table 89:Hologic, Inc. Pipeline Products By Development Stage 148
Table 90:Hologic, Inc. Pipeline Products By Therapy Area 148
Table 91:Hologic, Inc. Pipeline Products By Clinical Trials 148
Table 92:Hologic, Inc. Pipeline Products By News Summary 149
Table 93:Gen-Probe Incorporated Pipeline Products by Equipment Type 150
Table 94:Gen-Probe Incorporated Pipeline Products By Development Stage 151
Table 95:Gen-Probe Incorporated Pipeline Products By Therapy Area 151
Table 96:Gen-Probe Incorporated Pipeline Products By Clinical Trials 151
Table 97:Gen-Probe Incorporated Pipeline Products By News Summary 152
Table 98:DiaSorin S.p.A Pipeline Products by Equipment Type 154
Table 99:DiaSorin S.p.A Pipeline Products By Development Stage 154
Table 100:DiaSorin S.p.A Pipeline Products By Therapy Area 154
Table 101:Becton, Dickinson and Company Pipeline Products by Equipment Type 157
Table 102:Becton, Dickinson and Company Pipeline Products By Development Stage 158
Table 103:Becton, Dickinson and Company Pipeline Products By Therapy Area 158
Table 104:Becton, Dickinson and Company Pipeline Products By Clinical Trials 159
Table 105:Becton, Dickinson and Company Pipeline Products By News Summary 159
Table 106:Beckman Coulter, Inc. Pipeline Products by Equipment Type 160
Table 107:Beckman Coulter, Inc. Pipeline Products By Development Stage 161
Table 108:Beckman Coulter, Inc. Pipeline Products By Therapy Area 162
Table 109:Beckman Coulter, Inc. Pipeline Products By News Summary 162
Table 110:Abbott  Laboratories Pipeline Products by Equipment Type 163
Table 111:Abbott  Laboratories Pipeline Products By Development Stage 163
Table 112:Abbott  Laboratories Pipeline Products By Therapy Area 163
Table 113:AdnaGen AG Pipeline Products by Equipment Type 164
Table 114:AdnaGen AG Pipeline Products By Development Stage 164
Table 115:AdnaGen AG Pipeline Products By Therapy Area 165
Table 116:AdnaGen AG Pipeline Products By Clinical Trials 165
Table 117:AdnaGen AG Pipeline Products By News Summary 165
Table 118:Invitek Biotechnolgy & Biodesign Ltd. Pipeline Products by Equipment Type 168
Table 119:Invitek Biotechnolgy & Biodesign Ltd. Pipeline Products By Development Stage 168
Table 120:Invitek Biotechnolgy & Biodesign Ltd. Pipeline Products By Therapy Area 169
Table 121:Epigenomics AG Pipeline Products by Equipment Type 171
Table 122:Epigenomics AG Pipeline Products By Development Stage 171
Table 123:Epigenomics AG Pipeline Products By Therapy Area 171
Table 124:Epigenomics AG Pipeline Products By Clinical Trials 172
Table 125:Epigenomics AG Pipeline Products By News Summary 172
Table 126:8sens.biognostic GmbH Pipeline Products by Equipment Type 174
Table 127:8sens.biognostic GmbH Pipeline Products By Development Stage 174
Table 128:8sens.biognostic GmbH Pipeline Products By Therapy Area 174
Table 129:GPC Biotech Receives Approval To Merge With Agennix 175
Table 130:Thermo Fisher Scientific To Acquire B.R.A.H.M.S. 176
Table 131:Sonic Healthcare To Acquire 100% Of Lademannbogen Laboratory 177
Table 132:TOPTICA Photonics Acquires TILL Photonics From Agilent Technologies 178
Table 133:STRATEC Biomedical Systems Acquires Invitek 179
Table 134:Epigenomics Signs Licensing Agreement With ARUP Laboratories 180
Table 135:IVAX Diagnostics Signs Distribution Agreement With Augurix 181
Table 136:Celera Enters Into Licensing Agreement With Bayer Schering Pharma 182
Table 137:Epigenomics Enters Into An Agreement With Quest Diagnostics 183
Table 138:Kreatech Enters Into An Agreement With BioMicro Systems 184
Table 139:Medizinische Hochschule Hannover Signs An Agreement With Roche Diagnostics 185
Table 140:Exiqon Signs An Agreement With Roche Diagnostics 186
Table 141:SIRS-Lab Enters Into An Agreement With DxS 187
Table 142:   USD to Local Currency, Average Exchange Rate 2008 200

1.2 List of Figures
Figure 1: Healthcare Expenditure Sources in Germany, 2006 29
Figure 2: Healthcare Financing Framework in Germany, 2007 30
Figure 3: Flowchart for Classification of Non-invasive Devices in Germany, 2007 40
Figure 4: Flowchart for Classification of Invasive Devices in Germany, 2007 41
Figure 5: Flowchart for Classification of Invasive Devices in Germany, 2007 42
Figure 6: Classification of Invasive Devices in Germany, 2007 43
Figure 7: Classification of Invasive Devices in Germany, 2007 44
Figure 8: Flowchart for Classification of Active Devices in Germany, 2007 45
Figure 9: Flowchart for Classification of Active Devices in Germany, 2007 46
Figure 10: Flowchart for Classification of Devices except Non-invasive, Invasive and Active Devices in Germany, 2007 47
Figure 11: Conformity Assessment of Class-I Medical Devices in Germany, 2007 48
Figure 12: Conformity Assessment of Class-IIa Medical Devices in Germany, 2007 49
Figure 13: Conformity Assessment of Class-IIb Medical Devices in Germany, 2007 50
Figure 14: Conformity Assessment of Class-III Medical Devices in Germany, 2007 51
Figure 15:In Vitro Diagnostics, Germany, Overall Revenue ($ mn), 2000-2015 55
Figure 16:     In Vitro Diagnostics, Germany, Cross-Category Analysis, 2000-2015 56
Figure 17:In Vitro Diagnostics, Germany, Overall Revenue ($ mn), Historic, 2000-2008 57
Figure 18:In Vitro Diagnostics, Germany, Overall Revenue ($ mn), Forecast, 2008-2015 59
Figure 19:In Vitro Diagnostics, Germany, Company Share (%), 2008 61
Figure 20:Clinical Chemistry, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 62
Figure 21:Clinical Chemistry, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 64
Figure 22:Clinical Chemistry Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 66
Figure 23:Clinical Chemistry Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 67
Figure 24:Urine Analysis, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 68
Figure 25:Urine Analysis, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 69
Figure 26:Clinical Chemistry, Germany, Company Share (%), 2008 71
Figure 27:Genetic Testing, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 72
Figure 28:Genetic Testing, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 73
Figure 29:Genetic Testing, Germany, Company Share (%), 2008 75
Figure 30:Haematology, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 76
Figure 31:Haematology, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 78
Figure 32:Haematology Reagents, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 80
Figure 33:Haematology Reagents, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 81
Figure 34:Immunohaematology, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 82
Figure 35:Immunohaematology, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 83
Figure 36:Haemostasis, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 84
Figure 37:Haemostasis, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 86
Figure 38:Haematology Rapid Tests, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 88
Figure 39:Haematology Rapid Tests, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 89
Figure 40:Haematology Cell Counters, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 90
Figure 41:Haematology Cell Counters, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 91
Figure 42:Haematology, Germany, Company Share (%), 2008 93
Figure 43:Histology And Cytology, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 95
Figure 44:Histology and Cytology, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 96
Figure 45:Histology, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 97
Figure 46:Histology, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 98
Figure 47:Histology and Cytology, Germany, Company Share (%), 2008 100
Figure 48:Immuno Chemistry, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 101
Figure 49:Immuno Chemistry, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 103
Figure 50:Disease Specific Immunochemistry, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 105
Figure 51:Disease Specific Immunochemistry, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 107
Figure 52:Drug Related Testing, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 109
Figure 53:Drug Related Testing, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 110
Figure 54:Endocrinology Tests, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 111
Figure 55:Endocrinology Tests, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 112
Figure 56:Immunochemistry Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 113
Figure 57:Immunochemistry Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 115
Figure 58:Immuno Chemistry, Germany, Company Share (%), 2008 118
Figure 59:Infectious Immunology, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 120
Figure 60:Infectious Immunology, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 122
Figure 61:Infectious Immunology, Germany, Company Share (%), 2008 125
Figure 62:Microbiology Culture, Germany, Revenue ($ mn) by Segment, Historic, 2000-2008 127
Figure 63:Microbiology Culture, Germany, Revenue ($ mn) by Segment, Forecast, 2008-2015 129
Figure 64:Microbiology Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 131
Figure 65:Microbiology Analyzers, Germany, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 132
Figure 66:Microbiology Culture, Germany, Company Share (%), 2008 134
Figure 67: Methodology 197